PUBLIC COMPANY
save$CRBUCaribou Biosciences, Inc.
$CRBUBerkeley, CA, USupdated 2mo ago
Rachel Elizabeth Haurwitz is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Long-Term Follow-up Study
- phase1CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- phase1CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
- phase1CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- phase1CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
🐶 Hiring Signal
Where Caribou Biosciences, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 5
News
no news has mentioned this company yet
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that